ASRT
Assertio Holdings, Inc.Company with tickers: ASRT
CIK
1808665
CUSIP
04546C304
Shares Outstanding
6,462,180
Website
https://www.assertiotx.com
Investor Relations
https://investor.assertiotx.com/overview/default.aspx
13F Activity (30d)
6 filings
6 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | $9,933,000 | USD | 2026-03-31 | 10-Q | 2026-05-08 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | — | ||||
| Research & Development | $454,000 | USD | 2026-03-31 | 10-Q | 2026-05-08 |
| Operating Income | $-18,470,000 | USD | 2026-03-31 | 10-Q | 2026-05-08 |
| Net Income | $-18,856,000 | USD | 2026-03-31 | 10-Q | 2026-05-08 |
| EPS (Basic) | $-2.93 | USD/shares | 2026-03-31 | 10-Q | 2026-05-08 |
| EPS (Diluted) | $-2.93 | USD/shares | 2026-03-31 | 10-Q | 2026-05-08 |
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
By Product & Service (USD)
| Component | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|---|---|
| Product | $92,090,000 | $109,420,000 | $155,121,000 | $149,451,000 | $120,849,000 | $117,100,000 |
| ROLVEDON | — | — | $0 | $18,175,000 | $60,090,000 | $68,225,000 |
| INDOCIN Products | $31,684,000 | $60,557,000 | $100,338,000 | $87,217,000 | $26,761,000 | $18,905,000 |
| Sympazan | — | — | $1,768,000 | $9,938,000 | $10,457,000 | $11,349,000 |
| Product Other | $7,693,000 | $5,030,000 | $4,673,000 | $4,875,000 | $15,917,000 | $10,669,000 |
| SPRIX Nasal Spray | $11,077,000 | $8,676,000 | $9,110,000 | $9,150,000 | $7,624,000 | $7,952,000 |
| Royalty | — | — | — | — | $2,012,000 | $1,613,000 |
| Product And Service Other | $1,408,000 | $-985,000 | $-1,290,000 | $185,000 | $2,100,000 | $0 |
| CAMBIA | $28,350,000 | $24,972,000 | $24,720,000 | $8,070,000 | $5,556,000 | — |
| Commercialization Agreement | $11,258,000 | $0 | — | — | — | — |
| Other Revenue | $1,408,000 | $-985,000 | $-1,290,000 | — | — | — |
| Otrexup | — | $0 | $11,148,000 | $12,026,000 | $8,842,000 | — |
| Royalties And Milestones | $1,519,000 | $2,579,000 | $2,403,000 | $2,433,000 | $2,012,000 | — |
| Sympazam | — | $0 | $1,768,000 | — | — | — |
| Zipsor | $13,286,000 | $10,185,000 | $3,364,000 | $3,460,000 | — | — |